2022 World Conference on Lung Cancer (Posters)-P2.14-04. Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches

Pdf Summary

Researchers have redefined the classification of lung adenocarcinoma (LUAD) subtypes based on the differential expression of landmark pathways. The study identified seven subtypes of LUAD that differ in survival outcomes and molecular characteristics. This new classification could lead to more precise therapeutic strategies for patients without actionable genomic alterations. The study was funded by the Ministerio de Ciencia, Innovación y Universidades and received support from the European Regional Development Fund.<br /><br />LUAD is characterized by clinical and genetic heterogeneity, and current diagnostic practices do not fully capture this diversity. To address this, the researchers used gene expression profiling of molecular pathways to develop a consensus classification of LUAD patients. This classification could improve patient stratification and treatment decision-making.<br /><br />The study analyzed 56 LUAD datasets, comprising 4,573 patients. The researchers used the GSVA algorithm to evaluate pathway relative activity and performed clustering analysis. They identified seven LUAD subtypes based on the joint behavior of 50 pathways.<br /><br />The classification revealed differences in driver alterations frequency and overall survival among the subtypes. Genomic characterization showed that mutated samples of genes EGFR and KRAS fell into the same transcriptional subtype, challenging previous assumptions about the exclusivity of genomic subtypes. Additionally, the study identified potential drug candidates based on LUAD cell lines' response to targeted therapies and chemotherapy agents.<br /><br />In conclusion, the researchers propose a robust classification of LUAD subtypes based on pathway expression profiles. This classification has implications for personalized therapy beyond DNA-based targeted therapies and could improve treatment outcomes for patients with LUAD. Further research is warranted to validate and refine this classification system.

Asset Subtitle

Sara Hijazo-Pechero, Spain

Meta Tag

Speaker Sara Hijazo-Pechero, Spain

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

Keywords

lung adenocarcinoma

LUAD subtypes

differential expression

landmark pathways

survival outcomes

molecular characteristics

gene expression profiling

patient stratification

targeted therapies

classification system